Blog: Engaging Innovation | Friends of Cancer Research

Authored on

And

Max Chan | September 29, 2021

Watch Now: “Beyond Breakthrough: Optimizing the Breakthrough Therapy Designation”

On Monday, September 20th, 2021, Friends of Cancer Research (Friends) hosted a virtual event that brought together industry experts, the U.S. FDA, and patient advocates to discuss improving the…

Learn more

Grace Collins and Eric Hua | September 14, 2021

Beyond Breakthrough: Key Challenges Between FDA and Sponsors

This is the second of two blog posts highlighting Friends’ upcoming September 20th event discussing the Breakthrough Therapy designation (BTD). This post will focus on the key challenges between the…

Learn more

Max Chan | September 2, 2021

Beyond Breakthrough: Use of Innovative Drug Pathways at FDA

This is the first of two blog posts highlighting Friends’ upcoming September 20th event discussing the Breakthrough Therapy designation (BTD). In this post, we will summarize the recent history of…

Learn more

Lauren Grunley | August 19, 2021

What science, informed hope, and the FDA, gave my mother

A few weeks ago, a news story about a new drug caught my attention. The drug was described as the first potential treatment for Alzheimer’s disease in some 20 years. To be clear, I don’t have a…

Learn more

Max Chan | August 4, 2021

Watch Now: 21st Century Cures 2.0 Listening Session - Harnessing the Power of Collaboration

On July 29th, 2021, Friends of Cancer Research (Friends) hosted a virtual meeting revolving around the recently released 21st Century Cures 2.0 discussion draft. It featured a discussion panel of…

Learn more

July 15, 2021

How Will Expanded Eligibility Criteria Improve Access to Clinical Trials for Patients with Cancer?

Creating a New Cancer Research Paradigm by Broadening Eligibility Criteria The American Society of Clinical Oncology (ASCO, a professional society for cancer clinicians and researchers) and Friends…

Learn more

July 7, 2021

How Will Expanded Eligibility Criteria Impact Clinical Trial Design?

Learn more